Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT02516605
Other study ID # CLJN452X2201
Secondary ID 2015-001590-41
Status Completed
Phase Phase 2
First received
Last updated
Start date September 9, 2015
Est. completion date August 2, 2018

Study information

Verified date October 2019
Source Novartis
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

A multi-part study to assess safety, tolerability and efficacy of tropifexor (LJN452) in patients with primary biliary cholangitis


Recruitment information / eligibility

Status Completed
Enrollment 61
Est. completion date August 2, 2018
Est. primary completion date August 2, 2018
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years - Diagnosis of PBC as demonstrated by the presence of at least 2 of the following 3 diagnostic criteria: - History of alkaline phosphatase (ALP) elevated above upper limit of normal (ULN) for at least 6 months - Positive antimitochondrial antibodies (AMA) titer or if AMA negative or in low titer (<1:80) PBC specific antibodies (anti-GP210 and/or anti-SP100 and/or antibodies against the major M2 components (PDC-E2, 2-oxo-glutaric acid dehydrogenase complex)) - Previous liver biopsy findings consistent with PBC - At least 1 of the following markers of disease severity: - ALP = 1.67 × ULN - Total bilirubin > ULN but < 1.5 × ULN - In addition, patients must meet the following biochemical criteria at enrollment: - Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) = 5 × ULN - Total bilirubin = 1.5 × ULN - INR = ULN - Taking UDCA for at least 12 months, or for at least 6 months and has reached maximal response to UDCA with a plateau in alkaline phosphatase, with no changes in dose for = 3 months prior to Day 1. - Patients must weigh at least 40 kg to participate in the study, and must have a body mass index (BMI) within the range of 18 - 40 kg/m2. BMI = Body weight (kg) / [Height (m)]2 Exclusion Criteria: - Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unless they are using highly effective methods of contraception for 30 days before randomization, during dosing and for 30 days following the end of treatment. - Presence of other concomitant liver diseases. - Cirrhosis with complications, including history or presence of: - Variceal bleed - Uncontrolled ascites - Encephalopathy - Spontaneous bacterial peritonitis - Significant hepatic impairment as defined by Child-Pugh classification of B or C, history of liver transplantation, current placement on a liver transplant list or current Model for End Stage Liver Disease (MELD) score =15. - History of conditions that may cause increases in ALP (e.g., Paget's disease). - Use of investigational drugs, or immunosuppressive drugs at the time of enrollment, or within 5 half-lives, or 30 days of randomization, whichever is longer; or longer if required by local regulations. Use of high dose oral steroids to treat co-morbid conditions (e.g., airways disease) will be allowed but must be properly documented as such in concomitant medications. - Currently taking obeticholic acid or have taken obeticholic acid within 30 days of randomization - Previous participation in CLJN452X2201 and received study medication within three months of randomization (or longer if required by local regulations).

Study Design


Intervention

Drug:
Part 1: LJN452
LJN452 capsules administered once daily for 28 days
Part 1: Placebo
Matching placebo capsules administered once daily for 28 days
Part 2: LJN452 Dose level 1
LJN452 capsules administered once a day for 12 weeks
Part 2: Placebo
Matching placebo to LJN452 administered once a day for 12 weeks
Part 2: LJN452 Dose level 2
LJN452

Locations

Country Name City State
Canada Novartis Investigative Site Calgary Alberta
Canada Novartis Investigative Site Edmonton Alberta
Germany Novartis Investigative Site Hamburg
Germany Novartis Investigative Site Hannover
Germany Novartis Investigative Site Heidelberg
Germany Novartis Investigative Site Muenchen
Germany Novartis Investigative Site Wuerzburg
Poland Novartis Investigative Site Lodz
Poland Novartis Investigative Site Myslowice
Poland Novartis Investigative Site Warsaw
Poland Novartis Investigative Site Wroclaw
Russian Federation Novartis Investigative Site Moscow
Russian Federation Novartis Investigative Site Saint-Petersburg
Russian Federation Novartis Investigative Site Samara
United Kingdom Novartis Investigative Site Birmingham West Midlands
United Kingdom Novartis Investigative Site Cambridge
United Kingdom Novartis Investigative Site Hull
United Kingdom Novartis Investigative Site London
United Kingdom Novartis Investigative Site Newcastle upon Tyne
United States Novartis Investigative Site Atlanta Georgia
United States Novartis Investigative Site Chicago Illinois
United States Novartis Investigative Site Dallas Texas
United States Novartis Investigative Site Manhasset New York
United States Novartis Investigative Site Marietta Georgia
United States Novartis Investigative Site Miami Florida
United States Novartis Investigative Site Rialto California
United States Novartis Investigative Site San Antonio Texas
United States Novartis Investigative Site Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Novartis Pharmaceuticals

Countries where clinical trial is conducted

United States,  Canada,  Germany,  Poland,  Russian Federation,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Fold Change in Serum Gamma-glutamyl Transferase (GGT) Fold change in serum gamma-glutamyl transferase (GGT) from baseline to Day 28 Baseline to Day 28
Primary Blood Pressure Vital signs - Systolic Blood pressure Screening, Baseline, day 1, day 7, day 14, day 21, day 28, day 56, day 84
Primary Pulse Rate Vital signs Screening, Baseline, day 1, day 7, day 14, day 21, day 28, day 56, day 84
Primary Body Temperature Vital signs Screening, Baseline, day 1, day 7, day 14, day 21, day 28, day 56, day 84
Primary ECG - Heart Rate Electrocardiogram (ECG) Screening, Baseline, day 1, day 28
Primary ECG Intervals - PR Interval Electrocardiogram (ECG) Screening, Baseline, day 1, day 28
Primary Haemoglobin Hematology panel for safety laboratory assessments. Screening, Baseline, day 1, day 7, day 14, day 21, day 28, day 56, day 84
Secondary Plasma PK Parameter - AUC 0-8h Tropifexor levels were determined in plasma using a validated LC-MS/MS method. AUC0-t=The area under the plasma concentration-time curve from time zero to time 't' where t is a defined time point after administration [mass x time / volume] Day 1, Day 28
Secondary Plasma PK Parameter - Cmax Tropifexor levels were determined in plasma using a validated LC-MS/MS method. Cmax=The observed maximum plasma concentration following drug administration [mass /volume] Day 1, Day 28
Secondary Plasma PK Parameter - Tmax Tropifexor levels were determined in plasma using a validated LC-MS/MS method. Tmax = The time to reach the maximum concentration after drug administration [time] Day 1, Day 28
Secondary Changes From Baseline in Total PBC-40 Score Baseline is defined as the latest available predose value. The PBC-40 is a paper-based, patient-derived, disease-specific health-related quality of life (HRQOL) patient reported outcome (PRO) measure which was developed and validated for use in PBC patients (Jacoby et al 2005). It consists of 40 questions arranged in 6 domains with between 3 and 11 questions in each domain. Each question is scored from 1 to 5 in increasing order of severity. All questions within a domain are summed and all domain totals are summed to obtain a total score. The total score range is between a minimum of 40 and a maximum of 200. Higher scores represent a poorer quality of life. The median difference from baseline in total sum score for each treatment group is presented. Baseline, Day 28, Day 56, Day 84
Secondary Change From Baseline in Itch Subdomain of PBC-40 Score Baseline is defined as the latest available predose value. The PBC-40 is a paper-based, patient-derived, disease-specific health-related quality of life (HRQOL) patient reported outcome (PRO) measure which was developed and validated for use in PBC patients (Jacoby et al 2005). It consists of 40 questions arranged in 6 domains with between 3 and 11 questions in each domain. Each question is scored from 1 to 5 in increasing order of severity. This dataset focuses on the itch subdomain which consists of 3 questions. These 3 questions within the itch subdomain are summed to obtain a total score for the itch subdomain. The total score range is between a minimum of 3 and a maximum of 15. Higher scores represent a poorer quality of life. The median change from baseline in total itch subdomain score in each treatment group is presented. Baseline, Day 28, Day 56, Day 84
Secondary Change From Baseline in Global Itch Visual Analogue Scale (VAS) Baseline is defined as the latest available predose value. The Global Itch Visual Analogue Scale, a 100 mm visual analogue scale (VAS), was used to assess the severity of patients itch (ranging from 0 = none at all to 100 = the worst imaginable itch). The score range is between a minimum of 0 and a maximum of 100. The score (distance in mm from left) on the VAS was recorded by the patient marking with a line and used to test for an effect of tropifexor over placebo. The mean change from baseline in itch VAS score in each treatment group is presented. Day 7, Day 14, Day 21, Day 28, Day 56, and Day 84
See also
  Status Clinical Trial Phase
Recruiting NCT06051617 - Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and Compensated Cirrhosis Phase 3
Recruiting NCT06060665 - IDEAL: Intended to Determine the Effects of Seladelpar on Normalization of Alkaline Phosphatase Levels in Subjects With Primary Biliary Cholangitis (PBC) and an Incomplete Response or Intolerance to Ursodeoxycholic Acid (UDCA) Phase 3
Recruiting NCT05450887 - Efficacy and Safety of Obeticholic Acid in the Treatment of Primary Biliary Cholangitis Phase 3
Recruiting NCT05050136 - A Study to Evaluate Efficacy and Safety of an Investigational Drug Named Volixibat in Patients With Itching Caused by Primary Biliary Cholangitis Phase 2
Recruiting NCT05151809 - National Database on Primary Biliary Cholangitis
Recruiting NCT04076527 - Prospective, Multicenter Cohort Study on Primary Biliary Cholangitis
Recruiting NCT04950764 - An Open-Label Study Following Oral Dosing of Seladelpar to Subjects With Primary Biliary Cholangitis (PBC) and Hepatic Impairment (HI) Phase 1
Completed NCT03545672 - Early Identification of Myocardial Impairment in PBC
Completed NCT06098027 - Study of [14C]CS0159 in China Healthy Subjects Phase 1
Active, not recruiting NCT04594694 - Study of OCA in Combination With BZF Evaluating Efficacy, Safety, and Tolerability in Participants With PBC Phase 2
Completed NCT03602560 - ENHANCE: Seladelpar in Subjects With Primary Biliary Cholangitis (PBC) and an Inadequate Response to or an Intolerance to Ursodeoxycholic Acid (UDCA) Phase 3
Suspended NCT03684187 - Mindfulness - Based Intervention in the Treatment of Fatigue in Patients With Primary Biliary Cholangitis N/A
Recruiting NCT04617561 - Ursodeoxycholic Acid Combined With Low Dose Glucocorticoid in the Treatment of PBC With AIH Features II Phase 4
Terminated NCT03092765 - Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid Phase 2
Completed NCT04604652 - Open-Label Study of HTD1801 in Adult Subjects With Primary Biliary Cholangitis Phase 2
Not yet recruiting NCT06417398 - Preliminary Clinical Study of UTAA09 Injection in the Treatment of Relapsed/Refractory Autoimmune Diseases Early Phase 1
Recruiting NCT05919433 - Detection Program for Patients With Primary Biliary Cholangitis Lost in the System
Completed NCT06309589 - The Effectiveness of Combining Ursodeoxycholic Acid With Vitamin D in Treating Patients With Primary Biliary Cholangitis N/A
Completed NCT05292872 - Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients
Withdrawn NCT05293938 - A Real-World Data Study to Evaluate the Effectiveness of OCA on Hepatic Outcomes in PBC Patients